Debt Financing
Arrowhead pays $404.4 million to exit 15% Sixth Street loan, takes new $400 million loan at SOFR plus 5.50%
The refinancing ends a paid-in-kind loan and its payoff multiple, but the new interest is due in cash, the maturity moves out less than three months, and the covenants now allow far more convertible debt.

Arrowhead Pharmaceuticals, Inc. (Nasdaq: ARWR) paid about $404.4 million in cash on November 2, 2026 to retire its 15% Sixth Street term loan, and borrowed a new $400.0 million from the same lender group at three-month Term SOFR plus 5.50%. Chief Financial Officer Daniel Apel says the deal improves "the economics of our financing for shareholders," and the company's release says it improves near-term liquidity and extends maturity. The 8-K complicates both claims. The old loan's interest was paid in kind, while the new loan's interest is due in cash every quarter. The maturity moves out by less than three months. 8-K, November 4 press release
The payoff
Under the Financing Agreement dated August 7, 2024, the old term loans carried a fixed 15.0% rate, added to principal each period, and were due on August 7, 2031. On the closing date the outstanding balance was about $363.8 million, including interest paid in kind. Arrowhead used cash on hand to pay about $404.4 million, roughly $40.6 million above that balance, to cover all amounts owed under the agreement and its fee letter. The lenders accepted that sum in place of the multiple-of-invested-capital payment. The 8-K puts the saving at about $68 million against the 2.0x payment that would have been owed on repayment in full on or before August 7, 2028. The release adds that the multiple would have risen to 2.5x after that. 8-K, November 4 press release
The new loan
The Amended and Restated Financing Agreement provides a $400.0 million senior secured term loan, fully funded at closing, maturing on November 2, 2031. Arrowhead can choose three-month Term SOFR, with a 1.00% floor, plus 5.50%, or a base rate, with a 2.00% floor, plus 4.50%. With the SOFR floor, the rate is at least 6.50%, or at least $26 million a year in cash interest on the full balance. Arrowhead paid the lenders fees of 2.00% of principal, or $8.0 million, at closing. There is no amortization, so all principal falls due at maturity. 8-K
Prepayments in the first 18 months carry a make-whole premium. After that the premium is 2.00% for twelve months, then 1.00% for twelve months, then nothing. Arrowhead must still prepay from certain insurance and condemnation proceeds and from any debt the agreement does not permit. It no longer has to sweep plozasiran sales, royalties, milestones, licensing proceeds or proceeds from selling pipeline assets into repayment. The loan is secured on a first-priority basis by substantially all assets of Arrowhead and its subsidiary Arrowhead Madison Inc., including intellectual property, and Arrowhead Madison guarantees it. 8-K
Looser covenants
The minimum unrestricted cash covenant falls to $125.0 million, from $150.0 million. The agreement now allows more convertible debt, up to the greater of $1.1 billion and 10.0% of market capitalization. That basket is capped at $2.5 billion including the outstanding $700.0 million of 0.00% Convertible Senior Notes due 2032. Under the old agreement Arrowhead had no room left for more. Arrowhead can now out-license plozasiran (REDEMPLO) outside the United States and sell a priority review voucher without lender consent. In our reading, these terms give the company more room, and they also give it room to add debt on top of the $400.0 million secured loan and the $700.0 million of notes. 8-K
Who is on the deal
Sixth Street Lending Partners is administrative agent and collateral agent for the lenders, which the release calls funds managed by Sixth Street. Jeff Pootoolal, Partner, and Michael Reslinski, Managing Director at Sixth Street, said the new structure "recognizes that progress and supports the company's next phase of growth." Neither the 8-K nor the release names a financial advisor or legal counsel for either side. The credit agreement will be filed with the 10-Q for the quarter ending December 31, 2026. 8-K, November 4 press release
The balance sheet behind it
At June 30, 2026, Arrowhead held $1.547 billion of available-for-sale securities, $19.7 million of cash, cash equivalents and restricted cash, and $35.1 million of cash at its variable interest entity, Visirna Therapeutics. It lost $194.3 million attributable to Arrowhead in the quarter and $296.2 million over nine months, and used $79.5 million in operating cash over the nine months. Much of its revenue still comes from partners: $409.5 million of collaboration and license revenue in the nine months, mostly from Sarepta. The release gives no REDEMPLO sales figure, so it does not show how much of the new loan's cash interest product sales can carry. 10-Q, November 4 press release
What to watch
The fiscal 2026 annual report, for the year ended September 30, should show cash at that date, before the $404.4 million payoff. The December quarter 10-Q should show the first cash interest under the new rate and the full credit agreement. The release lists SOFR moves and the company's ability to service its debt and meet the new covenants among its risks. 8-K, November 4 press release
Investor Chat
Loading posts…
aibio